CSIMarket Company Name, Ticker, Competitors, else..
 


• Quick Ratio
• Working Capital
• LT Debt to Equity
• Debt to Equity
• Leverage Ratio
• Tangible Leverage
• Interest Coverage
• Debt Coverage
• Work. Cap. Per Revenue
Panbela Therapeutics Inc   (PBLA)
Other Ticker:  
 

Panbela Therapeutics Inc 's Long Term Debt to Equity

PBLA's quarterly Long Term Debt to Equity and Long Term Debt, Equity growth




PBLA Long Term Debt to Equity (Jun 30 2023)
II. Quarter		 (Mar 31 2023)
I. Quarter		 (Dec 31 2022)
IV. Quarter		 (Sep 30 2022)
III. Quarter		 (Jun 30 2022)
II. Quarter
Y / Y Equity Change - -61.48 % - - -
Y / Y Long Term Debt Change -19.25 % - - - -
Long Term Debt to Equity MRQ 0.87 1.65 - - -
Overall Ranking # 1485 # 1845 # 0 # 0 # 0
Seq. Equity Change 89.43 % - - - -
Seq. Long Term Debt Change 0 % -32.29 % 19.25 % 0 % -

New: More PBLA's historic Long Term Debt to Equity Ratios >>


Comment on PBLA Long Term Debt to Equity in the second quarter 2023
Due to long-term debt repayement of 0% Panbela Therapeutics Inc improved Long Term Debt to Equity in second quarter 2023 to 0.87, below the company's average Long Term Debt to Equity.

Within Major Pharmaceutical Preparations industry in the second quarter 2023, 70 other companies have achieved lower Long Term Debt to Equity than Panbela Therapeutics Inc in the II Quarter 2023. While Long Term Debt to Equity total ranking has improved so far in the second quarter 2023 to 1485, from total ranking in the first quarter 2023 at 1845.

Explain Long Term Debt to Equity Ratio?
How much Long Term Debt PBLA´s has?
What is the structure of PBLA´s Equity?
Long Term Debt to Equity second quarter 2023 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 71
Healthcare Sector # 197
Overall Market # 1485


Long Term Debt to Equity Statistics
High Average Low
1.65 0.88 0.31
(Mar 31 2023)   (Sep 30 2019)




Financial Statements
Panbela Therapeutics Inc 's Equity $ 5 Millions Visit PBLA's Balance sheet
Panbela Therapeutics Inc 's Long Term Debt $ 4 Millions Visit PBLA's Balance sheet
Source of PBLA's Sales Visit PBLA's Sales by Geography


Cumulative Panbela Therapeutics Inc 's Long Term Debt to Equity

PBLA's Long Term Debt to Equity for the trailling 12 Months

PBLA Long Term Debt to Equity

 (Jun 30 2023)
II. Quarter		 (Mar 31 2023)
I. Quarter		 (Dec 31 2022)
IV. Quarter		 (Sep 30 2022)
III. Quarter		 (Jun 30 2022)
II. Quarter
Y / Y Equity TTM Growth - -61.48 % - - -
Y / Y Long Term Debt TTM Growth -19.25 % - - - -
Long Term Debt to Equity TTM - - - 2.83 0.2
Total Ranking TTM # 1759 # 2300 # 0 # 222 # 0
Seq. Equity TTM Growth 89.43 % - - - -
Seq. Long Term Debt TTM Growth 0 % -32.29 % 19.25 % 0 % -

PBLA Company Profile >> Back to PBLA Financial Strength Comparisons >> Compare PBLA Debt to Equity Ratio to its Competitors

TTM Long Term Debt to Equity Comment
On the trailing twelve months basis Due to long-term debt repayement of 0% Panbela Therapeutics Inc improved Long Term Debt to Equity in the 12 months ending in II Quarter 2023 to -2.2, below the company's average Long Term Debt to Equity.
Long Term Debt to Equity is the average cumulative value over the last four quarters.

Among companies in the Major Pharmaceutical Preparations industry 70, during the past 12 months, other companies have achieved lower Long Term Debt to Equity than Panbela Therapeutics Inc . While Long Term Debt to Equity total ranking has improved so far to 1759, from total ranking in previous 12 month period at 2300.

Explain Long Term Debt to Equity Ratio?
How much Long Term Debt PBLA´s has?
What is the structure of PBLA´s Equity?

TTM Long Term Debt to Equity Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 71
Healthcare Sector # 197
Within the Market # 1485


TTM Long Term Debt to Equity Statistics
High Average Low
1.65 0.88 0.31
(Mar 31 2023)   (Sep 30 2019)




Companies with similar Long Term Debt to Equity in the quarter ending Jun 30 2023, within Major Pharmaceutical Preparations Industry Long Term Debt to EquityJun 30 2023 MRQ Long Term DebtJun 30 2023 MRQ Equity
Corbus Pharmaceuticals Holdings Inc   1.93 $ 18.335  Millions$ 9.521  Millions
Kala Bio inc   1.92 $ 33.569  Millions$ 17.492  Millions
Sarepta Therapeutics Inc   1.67 $ 1,235.517  Millions$ 741.411  Millions
Iterum Therapeutics Plc  1.64 $ 11.666  Millions$ 7.129  Millions
Eli Lilly And Company  1.63 $ 18,158.400  Millions$ 11,149.300  Millions
Jazz Pharmaceuticals Plc  1.61 $ 5,686.646  Millions$ 3,525.675  Millions
Phibro Animal Health Corporation  1.60 $ 452.541  Millions$ 282.509  Millions
Tempest Therapeutics Inc   1.49 $ 7.484  Millions$ 5.012  Millions
Trevena inc   1.45 $ 14.176  Millions$ 9.782  Millions
Zoetis Inc   1.42 $ 6,555.000  Millions$ 4,621.000  Millions
Alimera Sciences Inc   1.38 $ 63.954  Millions$ 46.230  Millions
Eyenovia inc   1.25 $ 13.177  Millions$ 10.522  Millions
Capricor Therapeutics inc   1.24 $ 3.376  Millions$ 2.731  Millions
Milestone Pharmaceuticals Inc   1.19 $ 48.073  Millions$ 40.408  Millions
Marinus Pharmaceuticals Inc   1.19 $ 68.136  Millions$ 57.339  Millions
Mallinckrodt Plc  1.18 $ 737.600  Millions$ 625.400  Millions
Bristol myers Squibb Company  1.08 $ 34,656.000  Millions$ 32,030.000  Millions
Cerevel Therapeutics Holdings Inc   0.96 $ 336.446  Millions$ 350.500  Millions
Madrigal Pharmaceuticals Inc   0.96 $ 99.249  Millions$ 103.506  Millions
Prestige Consumer Healthcare Inc   0.89 $ 1,316.711  Millions$ 1,480.295  Millions
G1 Therapeutics Inc   0.89 $ 50.936  Millions$ 57.548  Millions
Merck and Co Inc   0.88 $ 34,072.000  Millions$ 38,742.000  Millions
Panbela Therapeutics Inc   0.87 $ 4.194  Millions$ 4.802  Millions
Reata Pharmaceuticals Inc   0.84 $ 73.130  Millions$ 87.291  Millions
Perrigo Company Plc  0.84 $ 4,055.900  Millions$ 4,848.600  Millions
Summit Therapeutics Inc   0.84 $ 100.000  Millions$ 119.599  Millions
Amphastar Pharmaceuticals Inc   0.83 $ 488.280  Millions$ 589.235  Millions
Viatris Inc   0.83 $ 17,246.000  Millions$ 20,843.300  Millions
Elanco Animal Health Inc  0.81 $ 6,023.000  Millions$ 7,420.000  Millions
Cryoport inc   0.75 $ 408.339  Millions$ 544.255  Millions

Date modified: 2023-08-11T16:51:33+00:00



Help

About us

Advertise
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2023 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com